NASDAQ:IMUX Immunic Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.77 +0.30 (+8.65%) (As of 07/5/2022 04:00 PM ET) Add Compare Share Today's Range$3.41▼$3.7950-Day Range$3.13▼$7.8752-Week Range$2.52▼$14.50Volume178,629 shsAverage Volume480,175 shsMarket Capitalization$115.14 millionP/E RatioN/ADividend YieldN/APrice Target$21.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunic MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside476.9% Upside$21.75 Price TargetShort InterestHealthy6.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$127,380 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.86) to ($3.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.78 out of 5 starsMedical Sector627th out of 1,428 stocksPharmaceutical Preparations Industry306th out of 680 stocks 3.5 Analyst's Opinion Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.75, Immunic has a forecasted upside of 476.9% from its current price of $3.77.Amount of Analyst CoverageImmunic has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.22% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunic has recently increased by 22.58%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMUX. Previous Next 1.8 News and Social Media Coverage News SentimentImmunic has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immunic this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.MarketBeat Follows5 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have bought more of their company's stock than they have sold. Specifically, they have bought $127,380.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.00% of the stock of Immunic is held by insiders.Percentage Held by Institutions49.03% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunic are expected to decrease in the coming year, from ($2.86) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address About Immunic (NASDAQ:IMUX) StockImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.Read More IMUX Stock News HeadlinesJune 28, 2022 | finance.yahoo.comImmunic to Participate in Industry and Scientific Conferences in JulyJune 19, 2022 | americanbankingnews.comImmunic, Inc. (NASDAQ:IMUX) Short Interest UpdateJune 17, 2022 | streetinsider.comForm 4 IMMUNIC, INC. For: Jun 15 Filed by: Whaley Glenn - StreetInsider.comJune 15, 2022 | finance.yahoo.comImmunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational NeurologyJune 8, 2022 | finance.yahoo.comImmunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June - Yahoo FinanceJune 4, 2022 | benzinga.comSVB Leerink Maintains Outperform on Immunic, Lowers Price Target to $9 - Benzinga - BenzingaJune 3, 2022 | nasdaq.comImmunic (IMUX) Falls as Phase II Ulcerative Colitis Study Fails - NasdaqJune 3, 2022 | benzinga.comImmunic Shares Down 46%; Wedbush Lowers Price Target From $61 To $14 - Benzinga - BenzingaJune 2, 2022 | finance.yahoo.comImmunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update - Yahoo FinanceJune 2, 2022 | investing.comUS stocks higher at close of trade; Dow Jones Industrial Average up 1.33% By Investing.com - Investing.comJune 2, 2022 | benzinga.comMid-Afternoon Market Update: Dow Surges Over 150 Points; Immunic Shares Slide - Benzinga - BenzingaJune 2, 2022 | investorplace.comWhy is Immunic (IMUX) Stock Plunging 40% Today?June 2, 2022 | marketwatch.comImmunic Shares Hit New Lows After Ulcerative-Colitis Study Failure >IMUX - MarketWatchJune 2, 2022 | finance.yahoo.comImmunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate UpdateMay 20, 2022 | benzinga.comPiper Sandler Maintains Overweight on Immunic, Lowers Price Target to $39 - Benzinga - BenzingaMay 16, 2022 | finance.yahoo.comDuane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 166% More Shares - Yahoo FinanceMay 15, 2022 | finance.yahoo.comDuane Nash Is The Executive Chairman of Immunic, Inc. (NASDAQ:IMUX) And They Just Picked Up 166% More SharesMay 10, 2022 | investing.comImmunic Inc. Tops Q1 EPS by 6c By Investing.com - Investing.comMay 9, 2022 | benzinga.comEarnings Outlook For Immunic - Benzinga - BenzingaMay 5, 2022 | finance.yahoo.comImmunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac DiseaseMay 3, 2022 | finance.yahoo.comImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate UpdateApril 27, 2022 | globenewswire.comPrimary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight - GlobeNewswireApril 10, 2022 | finance.yahoo.comWhat You Need To Know About Immunic, Inc.'s (NASDAQ:IMUX) Investor Composition - Yahoo FinanceMarch 16, 2022 | finance.yahoo.comImmunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial OfficerMarch 10, 2022 | finance.yahoo.comImmunic, Inc. to Participate in Investor and Scientific Conferences in March - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees55Year FoundedN/ACompany Calendar Last Earnings11/04/2021Today7/05/2022Next Earnings (Estimated)8/05/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$21.75 High Stock Price Forecast$39.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+476.9%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.64% Return on Assets-54.46% Debt Debt-to-Equity RatioN/A Current Ratio10.11 Quick Ratio10.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book0.78Miscellaneous Outstanding Shares30,540,000Free Float29,013,000Market Cap$115.14 million OptionableNot Optionable Beta2.18 Immunic Frequently Asked Questions Should I buy or sell Immunic stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Immunic stock. View analyst ratings for Immunic or view top-rated stocks. What is Immunic's stock price forecast for 2022? 4 analysts have issued 12 month price objectives for Immunic's shares. Their IMUX stock forecasts range from $9.00 to $39.00. On average, they expect Immunic's share price to reach $21.75 in the next year. This suggests a possible upside of 476.9% from the stock's current price. View analysts' price targets for Immunic or view top-rated stocks among Wall Street analysts. How has Immunic's stock performed in 2022? Immunic's stock was trading at $9.57 on January 1st, 2022. Since then, IMUX shares have decreased by 60.6% and is now trading at $3.77. View the best growth stocks for 2022 here. When is Immunic's next earnings date? Immunic is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022. View our earnings forecast for Immunic. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.05. During the same quarter last year, the firm earned ($0.70) earnings per share. View Immunic's earnings history. Who are Immunic's key executives? Immunic's management team includes the following people: Dr. Duane D. Nash M.B.A., M.D., J.D., M.B.A, Exec. Chairman (Age 51, Pay $426.62k)Dr. Daniel Vitt, CEO, Pres & Director (Age 54, Pay $621.67k) (LinkedIn Profile)Mr. Glenn Whaley CPA, Chief Financial Officer (Age 54, Pay $448.48k) (LinkedIn Profile)Dr. Andreas Muehler M.D., Ph.D., Chief Medical Officer (Age 58, Pay $538.19k)Dr. Hella Kohlhof, Chief Scientific Officer (Age 49)Jessica Breu, Head of Investor Relations & CommunicationsMr. Inderpal Singh, Gen. Counsel (Age 56)Mr. Patrick Walsh, Chief Bus. Officer (Age 39) Who are some of Immunic's key competitors? Some companies that are related to Immunic include Amryt Pharma (AMYT), Intercept Pharmaceuticals (ICPT), Tango Therapeutics (TNGX), Esperion Therapeutics (ESPR), Dyne Therapeutics (DYN), Albireo Pharma (ALBO), Arbutus Biopharma (ABUS), Lexicon Pharmaceuticals (LXRX), Edgewise Therapeutics (EWTX), Karyopharm Therapeutics (KPTI), Protagonist Therapeutics (PTGX), BioXcel Therapeutics (BTAI), Generation Bio (GBIO), Vera Therapeutics (VERA) and Aerovate Therapeutics (AVTE). View all of IMUX's competitors. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and Ampio Pharmaceuticals (AMPE). What is Immunic's stock symbol? Immunic trades on the NASDAQ under the ticker symbol "IMUX." How do I buy shares of Immunic? Shares of IMUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunic's stock price today? One share of IMUX stock can currently be purchased for approximately $3.77. How much money does Immunic make? Immunic (NASDAQ:IMUX) has a market capitalization of $115.14 million. The company earns $-92,940,000.00 in net income (profit) each year or ($3.13) on an earnings per share basis. How many employees does Immunic have? Immunic employs 55 workers across the globe. How can I contact Immunic? Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The official website for Immunic is www.immunic-therapeutics.com. The company can be reached via phone at (332) 255-9818, via email at jessica.breu@immunic.de, or via fax at 858-673-6843. This page (NASDAQ:IMUX) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
